---
provider: openai
model: gpt-5
drug: Imatinib
disease: Chronic Myeloid Leukemia
query: 'Research the mechanism by which Imatinib affects Chronic Myeloid Leukemia.


  Produce a markdown response with EXACTLY this structure:


  ## Proposed mechanism summary

  2–3 paragraphs describing the mechanistic pathway from Imatinib to its effect

  on Chronic Myeloid Leukemia, with inline (PMID:XXXX) citations.


  ## Candidate PMIDs

  Bulleted list, 5–15 PMIDs ordered by relevance:

  - PMID:XXXXXXXX — One-sentence relevance note.

  - ...


  Only include PMIDs you verified exist via web search.


  ## Mechanism graph proposal (advisory)

  Drug → intermediate1 → intermediate2 → ... → Disease


  Each arrow labeled with a Biolink-style predicate (e.g., "decreases activity

  of", "positively regulates", "contributes to"). This topology is advisory —

  the curation agent will validate it.


  Output ONLY the markdown body. No preamble or closing remarks.

  '
generated_at: '2026-06-02T20:13:55+00:00'
ttl_days: 30
candidate_pmids:
- PMID:8616716
- PMID:8548747
- PMID:16572205
- PMID:11287972
- PMID:10988075
- PMID:7606002
- PMID:8402896
- PMID:8940193
- PMID:19843070
- PMID:10727459
- PMID:8758931
notes: input_tokens=104803, output_tokens=8243
---

## Proposed mechanism summary
Imatinib is a 2‑phenylaminopyrimidine tyrosine‑kinase inhibitor that binds the ATP pocket of ABL in its inactive (DFG‑out) conformation, thereby shutting down kinase activity of the BCR‑ABL oncoprotein that drives Chronic Myeloid Leukemia (CML). In BCR‑ABL–positive cells and primary CML progenitors, this selective ABL inhibition blocks BCR‑ABL autophosphorylation and phosphorylation of immediate substrates such as CRKL, halting proliferation and colony growth; the same target engagement underpins the profound clinical responses seen in CML patients treated with imatinib (PMID:8616716; PMID:8548747; PMID:16572205; PMID:11287972). Structural studies of the ABL–imatinib complex explain this selectivity and ATP‑competitive mechanism at atomic detail, confirming stabilization of the inactive ABL conformation (PMID:10988075).

Mechanistically, BCR‑ABL constitutively activates multiple survival and mitogenic pathways—including PI3K/AKT, RAS/MAPK via GRB2 binding to BCR Tyr177, and STAT5—each of which contributes to leukemic cell proliferation and resistance to apoptosis; imatinib suppresses these downstream signals in BCR‑ABL–dependent cells (PMID:7606002; PMID:8402896; PMID:8940193; PMID:19843070). A key apoptotic switch is STAT5: BCR‑ABL–STAT5 signaling maintains expression of the anti‑apoptotic gene BCL‑XL, and pharmacologic blockade of BCR‑ABL with an ABL‑selective inhibitor (including imatinib) reduces STAT5 activity and BCL‑XL, triggering apoptosis of CML cells (PMID:10727459). Together, direct inhibition of BCR‑ABL’s kinase activity and collapse of its STAT5/PI3K/RAS effector programs explain how imatinib reverses the leukemic phenotype in CML (PMID:8616716; PMID:11287972).

## Candidate PMIDs
- PMID:8616716 — Foundational preclinical paper showing a selective ABL inhibitor (prototype of imatinib) blocks growth of BCR‑ABL–positive cells and patient colony formation. ([go.drugbank.com](https://go.drugbank.com/articles/A249315))
- PMID:10988075 — Structural analysis demonstrating how imatinib binds the ATP site and stabilizes the inactive conformation of ABL, explaining selective BCR‑ABL inhibition. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/10988075/?utm_source=openai))
- PMID:11287972 — NEJM clinical study establishing efficacy and safety of the specific BCR‑ABL inhibitor in CML, validating on‑target disease modification. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11287972/?utm_source=openai))
- PMID:8548747 — Early characterization of the 2‑phenylaminopyrimidine scaffold (CGP‑57148) inhibiting Abl tyrosine kinase in vitro/in vivo, precursor to imatinib’s mechanism. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8548747/?utm_source=openai))
- PMID:10727459 — BCR‑ABL blockade suppresses STAT5‑dependent BCL‑XL expression and induces apoptosis in CML cells, linking target inhibition to cell death. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2193112/?utm_source=openai))
- PMID:8940193 — Demonstrates constitutive activation of STAT5 (and other STATs) by BCR‑ABL, identifying a major survival effector downstream of the oncoprotein. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8940193/?utm_source=openai))
- PMID:7606002 — Shows PI3K activity is regulated by BCR/ABL and required for growth of Ph‑positive cells, supporting a key pathway that imatinib disables indirectly. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8717045/?utm_source=openai))
- PMID:8402896 — Defines the GRB2 interaction with BCR‑ABL (via Tyr177) that drives RAS signaling, a mitogenic arm curtailed when BCR‑ABL kinase is inhibited. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8402896/?utm_source=openai))
- PMID:16572205 — Establishes CRKL phosphorylation as a surrogate of BCR‑ABL activity in CD34+ CML cells, reduced by imatinib; a practical readout of target engagement. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/16572205/?utm_source=openai))
- PMID:19843070 — Documents that imatinib lowers phosphorylation of BCR‑ABL and key effectors (e.g., STAT5/AKT) in CML cells, while revealing ERK exceptions that inform combination strategies. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/19843070/?utm_source=openai))
- PMID:8758931 — Shows activation of Src‑family kinases (Lyn/Hck) by p210BCR‑ABL in myeloid cells, part of the aberrant network suppressed when BCR‑ABL is inhibited. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8758931/?utm_source=openai))

## Mechanism graph proposal (advisory)
Imatinib → decreases activity of → BCR‑ABL1 tyrosine kinase (p210) → decreases activation of → STAT5 → decreases expression of → BCL‑XL (BCL2L1) → increases → apoptosis of leukemic myeloid progenitors → decreases → Chronic Myeloid Leukemia disease activity
